Hyde John E
Manchester Interdisciplinary Biocentre, Faculty of Life Sciences, University of Manchester, UK.
FEBS J. 2007 Sep;274(18):4688-98. doi: 10.1111/j.1742-4658.2007.05999.x.
Despite intensive research extending back to the 1930s, when the first synthetic antimalarial drugs made their appearance, the repertoire of clinically licensed formulations remains very limited. Moreover, widespread and increasing resistance to these drugs contributes enormously to the difficulties in controlling malaria, posing considerable intellectual, technical and humanitarian challenges. A detailed understanding of the molecular mechanisms underlying resistance to these agents is emerging that should permit new drugs to be rationally developed and older ones to be engineered to regain their efficacy. This review summarizes recent progress in analysing the causes of resistance to the major antimalarial drugs and its spread.
尽管自20世纪30年代第一种合成抗疟药物问世以来就进行了深入研究，但临床许可配方的种类仍然非常有限。此外，对这些药物的广泛且不断增加的耐药性极大地加剧了疟疾控制的困难，带来了相当大的智力、技术和人道主义挑战。对这些药物耐药性背后分子机制的详细理解正在浮现，这应该有助于合理开发新药，并对旧药进行改造以恢复其疗效。本综述总结了分析主要抗疟药物耐药性原因及其传播的最新进展。
